(Q42693733)

English

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).

scientific article published on 18 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

0 references

author name string

T Sugimoto

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

T Matsumoto

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

T Hosoi

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

T Miki

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

I Gorai

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

H Yoshikawa

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Y Tanaka

7

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

S Tanaka

8

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

M Fukunaga

9

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

T Sone

10

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

T Nakano

11

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

M Ito

12

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

S Matsui

13

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

T Yoneda

14

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

H Takami

15

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

K Watanabe

16

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

T Osakabe

17

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

N Okubo

18

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

M Shiraki

19

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

T Nakamura

20

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

language of work or name

0 references

publication date

18 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Osteoporosis International

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

765-774

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2964-2

21 January 2018

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/25403903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25403903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/25403903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00198-014-2964-2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42693733&oldid=2205615027"